NCT05174858

Brief Summary

This study is a multicentric randomised (2 groups, ratio 1:1) Post Market Clinical Follow-up trial. 38 subjects (teeth) requiring a simple tooth extraction or multiple tooth extraction on the same quadrant and taking curative or preventive antithrombotic treatment will be included (19 in each group). The aim of the study is to assess the efficacy of ETIK COLLAGENE (Topical hemostatic collagen-product) on the hemostasis (time to stop bleeding) after tooth extraction. The hemostasis is measured by assessing the presence of bleeding within the first 8 minutes post-extraction. Group 1: intra-alveolar placement of ETIK COLLAGENE immediately after tooth extraction. Group 2: the alveolus is left empty after tooth extraction (the use of ETIK COLLAGENE is delayed 8 minutes after tooth extraction, before suture). Subjects will be followed-up to 7 days.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
38

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Jan 2022

Shorter than P25 for not_applicable

Geographic Reach
1 country

2 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

December 13, 2021

Completed
21 days until next milestone

First Posted

Study publicly available on registry

January 3, 2022

Completed
22 days until next milestone

Study Start

First participant enrolled

January 25, 2022

Completed
4 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 20, 2022

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 20, 2022

Completed
Last Updated

June 1, 2022

Status Verified

May 1, 2022

Enrollment Period

4 months

First QC Date

December 13, 2021

Last Update Submit

May 30, 2022

Conditions

Keywords

Hemostasistooth extractionoral surgeryhuman

Outcome Measures

Primary Outcomes (1)

  • Assessment of time to hemostasis after tooth extraction

    For each patient, the time to stop bleeding (expressed in minutes) is assessed as follows : every 30 seconds from the tooth extraction (T0) to 8 minutes post extraction, the oral surgeon observes the alveolus during 5 seconds and records the presence or absence of bleeding.

    over 8 minutes after tooth extraction

Secondary Outcomes (4)

  • Rate of bleeding at 20 minutes

    20 minutes after tooth extraction

  • Occurrence of secondary post-extraction bleeding

    7 days

  • Level of pain after dental extraction by a numeric scale

    At the end of the oral surgery, day 1, day 2, day 3

  • Number of adverse and serious adverse events

    From the end of the oral surgery to Day 7

Study Arms (2)

Device under investigation

EXPERIMENTAL

intra-alveolar placement of the hemostatic dressing ETIK COLLAGENE immediately after tooth extraction.

Device: Hemostatic dressing ETIK COLLAGENE

Comparator

OTHER

the alveolus is left empty after tooth extraction.

Other: Comparator

Interventions

The hemostatic dressing ETIK COLLAGENE is placed in the alveolus immediately after tooth extraction. The presence of bleeding in the alveolus is assessed every 30 seconds for 8 minutes; then the surgical site is sutured.

Device under investigation

The alveolus is left empty after tooth extraction. The presence of bleeding in the alveolus is assessed every 30 seconds for 8 minutes; then the dressing ETIK COLLAGENE is placed in the alveolus and the surgical site is sutured.

Comparator

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Male or female, age \> 18 years old,
  • Patient undergoing a simple tooth extraction or multiple tooth extraction on the same quadrant,
  • Patient taking curative or preventive antithrombotic treatment or patient with a moderate thrombocytopenia,
  • Patient reachable after surgery,
  • Signed informed consent form,
  • Subject affiliated to a health insurance system, or is a beneficiary.

You may not qualify if:

  • Known allergy to bovine collagen,
  • Preoperative INR\<1.5 or \>3 or instable,
  • Patient with high risk of bleeding, history of postoperative hemorrhagic complication,
  • Treatment with bone resorption inhibitor, or patient irradiated at the cervico-facial level,
  • Contraindication to anesthesia using articaine with 1:200,000 epinephrine,
  • Clinical follow-up expected to be difficult,
  • Presence of uncontrolled hypertension, uncompensated diabetes or other clinically relevant systemic alterations,
  • Vulnerable subjects.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Faculté d'odontologie du CHU Nantes

Nantes, 44000, France

Location

CSD Rennes

Rennes, 35000, France

Location

MeSH Terms

Conditions

Tooth Avulsion

Condition Hierarchy (Ancestors)

Tooth InjuriesTooth DiseasesStomatognathic DiseasesWounds and Injuries

Study Officials

  • Flora THIBAUT, DDS

    Centre de soins dentaire CHU Rennes

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Masking Details
the participant will be blind from the treatment
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: Study subject will be randomized in a 1:1 allocation ratio between the 2 treatment groups
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

December 13, 2021

First Posted

January 3, 2022

Study Start

January 25, 2022

Primary Completion

May 20, 2022

Study Completion

May 20, 2022

Last Updated

June 1, 2022

Record last verified: 2022-05

Data Sharing

IPD Sharing
Will not share

Locations